Novartis CEO says China partnerships driven by science, not market strategy

Novartis chief executive Vas Narasimhan told reporters during the second quarter earnings call that the company’s recent agreements in China are motivated by scientific opportunities rather than a desire to simply expand its market presence.

He emphasized that the firm remains agnostic to geography and will pursue collaborations wherever the science justifies it, indicating that the China deals are a continuation of its existing R&D strategy.

Analysts view the comment as reassurance that the partnerships are grounded in pipeline development, which could support future revenue growth without signalling a major strategic shift.